DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced that its Board of Directors has nominated Brendan A. Ford and Eric K. Rowinsky, M.D. to serve as members of Neoprobe’s Board of Directors. Mr. Ford and Dr. Rowinsky have been nominated to stand for election at Neoprobe’s 2010 Annual Meeting of Stockholders scheduled for July 16th in Dublin, Ohio. Both Mr. Ford and Dr. Rowinsky have been nominated to serve as directors through Neoprobe’s stockholders’ meeting in 2013.
